Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia
Tóm tắt
Information on cost-effectiveness of interventions to treat schizophrenia can assist health policy decision making, particularly given the lack of health resources in developing countries like Thailand. This study aims to determine the optimal treatment package, including drug and non-drug interventions, for schizophrenia in Thailand. A Markov model was used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, olanzapine, clozapine and family interventions. Health outcomes were measured in disability adjusted life years. We evaluated intervention benefit by estimating a change in disease severity, taking into account potential side effects. Intervention costs included outpatient treatment costs, hospitalization costs as well as time and travel costs of patients and families. Uncertainty was evaluated using Monte Carlo simulation. A sensitivity analysis of the expected range cost of generic risperidone was undertaken. Generic risperidone is more cost-effective than typicals if it can be produced for less than 10 baht per 2 mg tablet. Risperidone was the cheapest treatment with higher drug costs offset by lower hospital costs in comparison to typicals. The most cost-effective combination of treatments was a combination of risperidone (dominant intervention). Adding family intervention has an incremental cost-effectiveness ratio of 1,900 baht/DALY with a 100% probability of a result less than a threshold for very cost-effective interventions of one times GDP or 110,000 baht per DALY. Treating the most severe one third of patients with clozapine instead of risperidone had an incremental cost-effectiveness ratio of 320,000 baht/DALY with just over 50% probability of a result below three times GDP per capita. There are good economic arguments to recommend generic risperidone as first line treatment in combination with family intervention. As the uncertainty interval indicates the addition of clozapine may be dominated and there are serious side effects, treating severe patients with clozapine is advisable only for patients who do not respond to risperidone and only in the presence of a stricter side effect monitoring system than currently exists.
Tài liệu tham khảo
Barbato A: Schizophrenia and public health. Geneva: World Health Organization; 1998.
Bundhamcharoen K, Teerawatananon Y, Vos T, Begg S: Burden of disease and injuries in Thailand: priority setting for policy. Nonthaburi: Ministry of Public Health; 2002.
Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull 2004, 30: 279–293.
Lang H-C, Su T-P: The Cost of Schizophrenia Treatment in Taiwan. Psychiatr Serv 2004, 55: 928–930. 10.1176/appi.ps.55.8.928
Chang SM, Cho S-J, Jeon HJ, Hahm B-J, Lee HJ, Park J-I, Cho MJ: Economic burden of schizophrenia in South Korea. Korean Med Sci 2008, 23: 167–175. 10.3346/jkms.2008.23.2.167
Kessler RC, Frank RG: The impact of psychiatric disorder on work loss days. Psychol Med 1997, 27: 861–873. 10.1017/S0033291797004807
Lang HC, Su TP: The cost of schizophrenia treatment in Taiwan. Psychiatr Serv 2004, 55: 928–930. 10.1176/appi.ps.55.8.928
Lee IH, Chen PS, Yang YK, Liao YC, Lee YD, Yeh TL, Yeh LL, Cheng SH, Chu CL: The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Res 2008, 158: 306–315. 10.1016/j.psychres.2006.10.004
Grover S, Avasth A, Chakrabart S, Bhansali A, Kulhara P: Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta psychiatr Scand 2005, 112: 55–63.
The Department of Mental Health MoPH: Annual report. Bkk: Department of Mental Health; 2008.
Pharmacoeconomic modelling in schizophrenia: trap or support for decision makers [http://www.rees-france.com/en/article.php3?id_article=470]
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 2009, 373: 31–41. 10.1016/S0140-6736(08)61764-X
Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P: Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidone. J Med Assoc Thai 2005, 88: 1267–1277.
Martin JLR, Perez V, Sacristan M, Rodriguez-Artalejo F, Martinez C, Alvarez E: Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry 2006, 21: 11. 10.1016/j.eurpsy.2005.09.009
Mari JdJ, Razzouk D, Thara R, Eaton J, Thornicroft G: Packages of care for schizophrenia in low- and middle-income countries. PLoS Med 2009, 6: 1–8.
Patterson TL, Leeuwenkamp OR: Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res 2008, 100: 108–119. 10.1016/j.schres.2007.12.468
Taylor T, Killaspy H, Wright C, Turton P, White S, Kallert T, Schuster M, Cervilla J, Brangier P, Raboch J, et al.: A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problems. BMC Psychiatry 2009, 9: 55. 10.1186/1471-244X-9-55
Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray C: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
Chisholm D: Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization. World Psychiatry 2005, 4: 37–44.
Phanthunane P, Chaipornsupaisan W, Vos T: A survey of severity, quality of life and current treatment patterns in people with schizophrenia in Thailand 2008. Bangkok: SPICE project; 2008.
Gold MR, Siegal JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. New York: Oxford University Press, Inc.; 1996.
Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T: Assessing cost-effectiveness of drug interventions for schizophrenia. Australian and New Zealand Journal of Psychiatry 2005, 39: 44–54.
Deeks JJ, Altman DG, Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. Edited by: Egger M, Smith GD, Altman D. London: BMJ Publishing Group; 2001:211–228.
Haby MM, Carter R, Mihalopoulos C, Magnus A, Sanderson K, Andrews G, Vos T: Assessing cost-effectiveness - mental health: introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004, 38: 569–578.
Duggan LFM, Rathbone J, Dardennes R, El-Dosoky A, Indran S: Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005.
Essali AA-HHN, Li C, Rathbone J: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009.
Hunter RHJC, Kennedy E, Gilbody SM, Song F: Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003.
Irving CBAC, Lawrie S: Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006.
Pekkala E, Merinder L: Psychoeducation for Schizophrenia. In Cochrane Database of Systematic Review. John Wiley & Sons, Ltd; 2002.
Pharoah F, Marit J, Rathbone J, Wong W: Family intervention for schizophrenia. In Cochrane Database of Systematic Reviews. John Wilet & Son, Ltd; 2006.
Phanthunane P, Vos T, Whiteford H, Bertram M: Health outcomes of schizophrenia in Thailand: Health care provider and patient perspectives. Asian Journal of Psychiatry 2010, 3: 200–205. 10.1016/j.ajp.2010.09.004
Stouthard ME, Essink-Bot M-L, Bonsel GJ, Barendregt JJ, Kramer PGN, Water HPAvd, Schepers LJG, Maas PJv: Disability weights for diseases in the Netherland. Rotterdam: Department of Public Health, Erasmus University Rotterdam; 1997.
Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry 1997, 170: 205–228. 10.1192/bjp.170.3.205
Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R: Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. 1999,175(576–580):576–580.
Harris EC, Barraclough B: Excess mortality of mental disorder. 1998,173(11–53):11–53.
Lacro JPDL, Dolder CR, et al.: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63: 892–909. 10.4088/JCP.v63n1007
Prukkanone B, Vos T, Burgess P, Chaiyakunapruk N, Bertram M: Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. BMC Psychiatry 2010, 10: 64. 10.1186/1471-244X-10-64
Matthew JB, Paul AN, Emmeline L: Antipsychotic Medication Adherence in Schizophrenia. The Psychiatric clinics of North America 2007, 30: 437. 10.1016/j.psc.2007.04.002
Valenstein M, Blow F, Copeland L, McCarthy J, Zeber J, Gillon L, Bingham C, Stavenger T: Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors. Schizophrenia Bulletin 2004, 30: 255.
Grunder G, Hippius H, Carlsson A: The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009, 8: 197–202. 10.1038/nrd2806
Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361: 1581–1589. 10.1016/S0140-6736(03)13306-5
Adams CE, Awad G, Rathbone J, Thornley B: Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007.
Cheng L-Y, Chan S: Psychoeducation Program for Chinese Family Carers of Members With Schizophrenia. West J Nurs Res 2005, 27: 583–599. 10.1177/0193945905275938
Matichon: The happiness of people with mental disorder-cheaper medications. Matichononline; 2009.
Vos T, Haby MM, Magnus A, Mihalopoulos C, Andrews G, Carter R: Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Australian and New Zealand Journal of Psychiatry 2005, 39: 701–712.
Tandon R, Targum SD, Nasrallah HA, Ross R: Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Journal of Psychiatric Practice 2006, 12: 348–363. 10.1097/00131746-200611000-00003
Chantarasak S: Study of safety and outcomes of clozapine for treatmetn of schizophrenia at Sruthunya hospital. Journal of Mental Health of Thailand 2003, 9: 82.
Kelvin MT, Fung HWHT, Patrick W Corrigan: Self-stigma of people with schizophrenia as predictor of their adherence to psychosocial treatment. Psychiatric Rehabilitation Journal 2008, 32: 95–104. 10.2975/32.2.2008.95.104
Heeg BMS, Damen J, Buskens E, Caleo S, Frank de C, van Hout BA: Modelling Approaches: The Case of Schizophrenia. PharmacoEconomics 2008, 26: 633–648. 10.2165/00019053-200826080-00002
Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002, 57: 201. 10.1016/S0920-9964(01)00309-7
Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J: Does switching to a new antipsychotic improve outcomes?: Data from the CATIE trial. Schizophr Res 2009, 107: 22–29. 10.1016/j.schres.2008.09.031
Obradovic M, Mrhar A, Kos M: Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007, 61: 1979–1988. 10.1111/j.1742-1241.2007.01431.x
Lindner LM, Marasciulo AC, Farias MR, Grohs GEM: Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian healthcare system. Rev Saúde Pública 2009, 43: 62–69.
Cooper D, Moisan J, Abdous B, Grégoire JP: A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia. Can J Clin Pharmacol 2008, 15: 385–397.
Chisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, Mendis N, Ayuso-Mateos J-L, Saxena S: Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. WHO bulletin 2008, 86: 542–551.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. Am J Psychiatry 1999, 156: 1686–1696.
Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C: Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Australian and New Zealand Journal of Psychiatry 2000, 34: 221.
Savilla K, Kettler L, Galletly C: Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Australian and New Zealand Journal of Psychiatry 2008, 42: 496–504. 10.1080/00048670802050512
Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL: Subjective and objective quality of life in schizophrenia. Schizophr Res 2008, 98: 201–208. 10.1016/j.schres.2007.09.001
Sitzer DITEW, Patterson TL, Jeste DV: Multivariate predictors of social skills performance in middle-aged and older out-patients with schizophrenia spectrum disorders. Psychological medicine 2008, 38: 755–763.
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). The Lancet 2009, 374: 620–627. 10.1016/S0140-6736(09)60742-X